Although the exact mechanism of how RET fusion promotes brain organotropism for tumor cells is not known, recent trial results in patients receiving the selective RET inhibitor selpercatinib demonstrated decreased CNS metastatic progression of RET fusion-positive NSCLC, with no CNS involvement at all in patients with no previous BMs [72]. The gene discussed is RET; the disease is non-small cell lung carcinoma.